Lumora and Promega said this week that they have signed an agreement for the use of Promega's Ultra-Glo luciferase in Lumora's bioluminescent assay in real time, or BART, molecular diagnostics technology.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now. Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Liquid biopsies and DNA tests may be able to tell physicians whether a cancer patient is relapsing, the New York Times reports.
In PLOS this week: GWAS links gene to noise-induced hearing loss in mice, population genetics of malaria parasites, and more.
Nautilus' Alexandra Ossola examines how Tay-Sachs disease jump-started the genetic disease testing field.
FASEB says guidelines proposed by the NIH to bolster research reproducibility are premature and don't take the full range of scientific studies into consideration.